Earnings call briefThird-quarter 2026

Thermo Fisher Scientific TMO

Thermo Fisher Scientific raises 2026 free cash flow outlook to $7 billion to $7.5 billion

Thermo Fisher Scientific assumes $4 billion of 2026 share buybacks, with $3 billion completed in January and $1 billion in the second quarter.

GetSignal 

Share
Download on the App StoreGet it on Google Play

Free on iOS and Android

Thermo Fisher Scientific said on its third-quarter call on October 21, 2026, that it expects net capital expenditures of $1.9 billion to $2 billion in 2026. At the midpoint, the company said it is increasing full-year adjusted EPS guidance by $0.15, including $0.05 from the net impact of tariff refund recovery after deploying about $40 million of additional reinvestment in the fourth quarter.

Quotes from the call

“We expect between $1.9 billion and $2 billion of net capital expenditures in 2026, and we are raising our expected free cash flow range to be between $7 billion and $7.5 billion for the year.”

Jim Meyer, Senior Vice President and Chief Financial Officer

“...we are assuming $4 billion of share buybacks, with $3 billion completed in January and $1 billion completed in the second quarter.”

Jim Meyer, Senior Vice President and Chief Financial Officer

Key facts from the call

Expected 2026 net capital expenditures
$1.9 billion to $2 billion
2026 free cash flow outlook
$7 billion to $7.5 billion
2026 share buybacks assumed
$4 billion

All TMO call briefs

Source: Thermo Fisher Scientific's third-quarter 2026 earnings call, October 21, 2026.

Written by GetSignal with AI from the company's earnings call. How we make news

Not investment advice.

More earnings call briefs

The newest

All earnings call briefs